However, challenges remain, such as the necessity for a dual chamber pen for the company's drug CagriSema, which could impact patient conversion rates. The report also highlighted the importance ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

The Identity pacemaker family, which includes the world's smallest dual-chamber pacemaker, provides clinicians with the most advanced pacemaker technology available, including the revolutionary AF ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...

Mexico's President Claudia Sheinbaum said on Sunday that reason should prevail a day after her government and the U.S. announced tariffs against one another, raising her fist in the air as she ...

Amycretin affects the same two targets as a Novo drug called cagrisema that recently missed expectations in a Phase 3 trial, but does so in a single molecule rather than a two-drug combination.

Love it or hate it, BOA is here to stay in ski boots. In fact, a handful of brands are getting rid of buckles entirely on some of the boots with the introduction of the new Dual BOA® Fit System. Yep, ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December.